/Dexcom%20Inc%20logo%20on%20sign-by%20Michael%20Vi%20via%20Shutterstock.jpg)
Despite DexCom’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.
This medical device company is down but not out.
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth.
The S&P 500 Index ($SPX ) (SPY ) Friday closed down by -0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.61%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.59%. Stocks...
The S&P 500 Index ($SPX ) (SPY ) today is up by +0.86%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.53%. Stocks today are moderately...
The S&P 500 Index ($SPX ) (SPY ) today is up by +0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.84%. Stocks today are moderately...
DXCM earnings call for the period ending September 30, 2024.
Recent developments might have scared away some investors, but patience could pay off.
A discounted stock can present an opportunity when there's a quality business behind it.